MacroGenics Reports FY Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MGNX?
Source: seekingalpha
- Earnings Performance: MacroGenics reported a FY GAAP EPS of -$1.18, beating expectations by $0.03, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Decline: The company generated $149.5 million in revenue for FY 2025, a 0.3% year-over-year decline, yet it surpassed market expectations by $13.38 million, demonstrating resilience in a competitive market.
- Cash Position: As of December 31, 2025, MacroGenics had a cash, cash equivalents, and marketable securities balance of $189.9 million, down from $201.7 million in 2024, reflecting challenges in cash management that may impact future R&D investments.
- FDA Regulatory Impact: Following a partial clinical hold imposed by the FDA on its lead program, MacroGenics' stock price dropped, highlighting the negative impact of regulatory risks on shareholder confidence and raising concerns about future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MGNX
Wall Street analysts forecast MGNX stock price to fall
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 3.430
Low
2.00
Averages
3.00
High
4.00
Current: 3.430
Low
2.00
Averages
3.00
High
4.00
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MacroGenics Antibody Drug Progress Expected in 2026
- Clinical Data Expectations: MacroGenics CEO Eric Risser indicated that the company anticipates reporting clinical data for antibody drug MGC026 in mid-2026 and for MGC028 in the second half of 2026, which could provide positive signals for the company's future market performance.
- Trial Application Plans: The company plans to submit a clinical trial application for MGC030 in the third quarter of 2026, further expanding its antibody drug pipeline and demonstrating its strategic positioning in the cancer treatment sector.
- FDA Clinical Hold: Although the company faced a partial clinical hold from the FDA on its study evaluating lorigerlimab, it is actively working with the agency and expects to provide updates in mid-2026, showcasing its ability to navigate regulatory challenges.
- Strong Financial Position: As of the end of 2022, the company reported cash and cash equivalents of $189.9 million, which is expected to support its operations into late 2027, providing a solid financial foundation for future R&D and market expansion.
See More
MacroGenics Stock Surpasses Analyst Target Price
- Price Target Breakthrough: MacroGenics, Inc (MGNX) shares recently rose to $3.43, surpassing the average analyst 12-month target price of $3.40, indicating optimistic market sentiment that may attract more investor interest.
- Diverse Analyst Reactions: Among analysts covered by Zacks, target prices range from $2.00 to $5.00, with a standard deviation of $1.14, highlighting significant divergence in market views on MGNX's future performance, necessitating careful risk assessment by investors.
- Investor Decision Signal: The stock's rise above the target price provides a signal for investors to reassess the company, prompting them to consider whether the current price is merely a stop on the way to higher targets or if it's time to think about taking profits.
- Wisdom of the Market: The average target price reflects the collective wisdom of multiple experts, and investors should pay attention to this data to better understand the overall market sentiment and potential trends for MGNX.
See More
MacroGenics Reports FY Earnings Beat Expectations
- Earnings Performance: MacroGenics reported a FY GAAP EPS of -$1.18, beating expectations by $0.03, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Decline: The company generated $149.5 million in revenue for FY 2025, a 0.3% year-over-year decline, yet it surpassed market expectations by $13.38 million, demonstrating resilience in a competitive market.
- Cash Position: As of December 31, 2025, MacroGenics had a cash, cash equivalents, and marketable securities balance of $189.9 million, down from $201.7 million in 2024, reflecting challenges in cash management that may impact future R&D investments.
- FDA Regulatory Impact: Following a partial clinical hold imposed by the FDA on its lead program, MacroGenics' stock price dropped, highlighting the negative impact of regulatory risks on shareholder confidence and raising concerns about future growth prospects.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
MacroGenics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: MacroGenics will participate in several investor conferences in March in Boston and Miami, with CEO Eric Risser scheduled to deliver a hybrid presentation at the TD Cowen conference on March 3, which is expected to attract investor interest and enhance the company's visibility.
- One-on-One Meeting Opportunities: Management will engage in one-on-one meetings at all conferences, providing potential investors with an in-depth understanding of the company's strategy and product pipeline, which could facilitate future investment decisions.
- Webcast Availability: All presentations will be accessible via live webcasts on the company's investor relations website, with a 30-day replay available, enhancing transparency and providing a follow-up opportunity for investors who cannot attend live.
- Technological Platform Advantage: MacroGenics focuses on developing innovative monoclonal antibody therapies, and its advanced technology platforms and protein engineering expertise have led to strategic collaborations with several global pharmaceutical and biotechnology companies, further solidifying its market position in cancer treatment.
See More
MacroGenics Faces FDA Partial Hold on Key Clinical Trial
- FDA Clinical Hold: MacroGenics announced a partial clinical hold on its mid-stage trial LINNET for its lead asset lorigerlimab, causing the company's stock to drop approximately 18% in premarket trading.
- Safety Event Reporting: The hold was initiated by the FDA following reports of safety events in four patients treated with lorigerlimab, including Grade 4 thrombocytopenia, myocarditis, and neutropenia, with one case resulting in a Grade 5 septic shock.
- Trial Participation Status: So far, 41 subjects have received 6 mg/kg of lorigerlimab every three weeks in the LINNET trial, and while new patient enrollment is halted, existing patients will continue to receive the experimental therapy.
- Market Reaction: The FDA's intervention introduces uncertainty regarding the progress of MacroGenics' clinical trials, which could impact the company's future drug approval plans and overall market performance.
See More
MacroGenics Antibody Drug Progress Expected in 2026
- Clinical Data Expectations: MacroGenics CEO Eric Risser indicated that the company anticipates reporting clinical data for antibody drug MGC026 in mid-2026 and for MGC028 in the second half of 2026, which could provide positive signals for the company's future market performance.
- Trial Application Plans: The company plans to submit a clinical trial application for MGC030 in the third quarter of 2026, further expanding its antibody drug pipeline and demonstrating its strategic positioning in the cancer treatment sector.
- FDA Clinical Hold: Although the company faced a partial clinical hold from the FDA on its study evaluating lorigerlimab, it is actively working with the agency and expects to provide updates in mid-2026, showcasing its ability to navigate regulatory challenges.
- Strong Financial Position: As of the end of 2022, the company reported cash and cash equivalents of $189.9 million, which is expected to support its operations into late 2027, providing a solid financial foundation for future R&D and market expansion.
See More
MacroGenics Stock Surpasses Analyst Target Price
- Price Target Breakthrough: MacroGenics, Inc (MGNX) shares recently rose to $3.43, surpassing the average analyst 12-month target price of $3.40, indicating optimistic market sentiment that may attract more investor interest.
- Diverse Analyst Reactions: Among analysts covered by Zacks, target prices range from $2.00 to $5.00, with a standard deviation of $1.14, highlighting significant divergence in market views on MGNX's future performance, necessitating careful risk assessment by investors.
- Investor Decision Signal: The stock's rise above the target price provides a signal for investors to reassess the company, prompting them to consider whether the current price is merely a stop on the way to higher targets or if it's time to think about taking profits.
- Wisdom of the Market: The average target price reflects the collective wisdom of multiple experts, and investors should pay attention to this data to better understand the overall market sentiment and potential trends for MGNX.
See More
MacroGenics Reports FY Earnings Beat Expectations
- Earnings Performance: MacroGenics reported a FY GAAP EPS of -$1.18, beating expectations by $0.03, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Decline: The company generated $149.5 million in revenue for FY 2025, a 0.3% year-over-year decline, yet it surpassed market expectations by $13.38 million, demonstrating resilience in a competitive market.
- Cash Position: As of December 31, 2025, MacroGenics had a cash, cash equivalents, and marketable securities balance of $189.9 million, down from $201.7 million in 2024, reflecting challenges in cash management that may impact future R&D investments.
- FDA Regulatory Impact: Following a partial clinical hold imposed by the FDA on its lead program, MacroGenics' stock price dropped, highlighting the negative impact of regulatory risks on shareholder confidence and raising concerns about future growth prospects.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
MacroGenics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: MacroGenics will participate in several investor conferences in March in Boston and Miami, with CEO Eric Risser scheduled to deliver a hybrid presentation at the TD Cowen conference on March 3, which is expected to attract investor interest and enhance the company's visibility.
- One-on-One Meeting Opportunities: Management will engage in one-on-one meetings at all conferences, providing potential investors with an in-depth understanding of the company's strategy and product pipeline, which could facilitate future investment decisions.
- Webcast Availability: All presentations will be accessible via live webcasts on the company's investor relations website, with a 30-day replay available, enhancing transparency and providing a follow-up opportunity for investors who cannot attend live.
- Technological Platform Advantage: MacroGenics focuses on developing innovative monoclonal antibody therapies, and its advanced technology platforms and protein engineering expertise have led to strategic collaborations with several global pharmaceutical and biotechnology companies, further solidifying its market position in cancer treatment.
See More
MacroGenics Faces FDA Partial Hold on Key Clinical Trial
- FDA Clinical Hold: MacroGenics announced a partial clinical hold on its mid-stage trial LINNET for its lead asset lorigerlimab, causing the company's stock to drop approximately 18% in premarket trading.
- Safety Event Reporting: The hold was initiated by the FDA following reports of safety events in four patients treated with lorigerlimab, including Grade 4 thrombocytopenia, myocarditis, and neutropenia, with one case resulting in a Grade 5 septic shock.
- Trial Participation Status: So far, 41 subjects have received 6 mg/kg of lorigerlimab every three weeks in the LINNET trial, and while new patient enrollment is halted, existing patients will continue to receive the experimental therapy.
- Market Reaction: The FDA's intervention introduces uncertainty regarding the progress of MacroGenics' clinical trials, which could impact the company's future drug approval plans and overall market performance.
See More
